|
Vassilev, A; Ozer, Z; Navara, C et al. (1999) Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex. J Biol Chem 274:1646-56
|
|
Chen, C L; Levine, A; Rao, A et al. (1999) Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies. J Clin Pharmacol 39:1248-55
|
|
Uckun, F M; Messinger, Y; Chen, C L et al. (1999) Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Clin Cancer Res 5:3906-13
|
|
Uckun, F M; Narla, R K; Zeren, T et al. (1998) In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor. Clin Cancer Res 4:1125-34
|
|
Ek, O; Yanishevski, Y; Zeren, T et al. (1998) In vivo toxicity and pharmacokinetic features of B43(Anti-CD19)-Genistein immunoconjugate. Leuk Lymphoma 30:389-94
|
|
Messinger, Y; Yanishevski, Y; Ek, O et al. (1998) In vivo toxicity and pharmacokinetic features of B43 (anti-CD19)-genistein immunoconjugate in nonhuman primates. Clin Cancer Res 4:165-70
|
|
Uckun, F M; Narla, R K; Jun, X et al. (1998) Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells. Clin Cancer Res 4:901-12
|
